Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
154studies shown
Showing 76-100 of 154
RecruitingNCT07424404

A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

This study is looking at care and outcomes for people with Schizophrenia or Autism-Related Irritability. Taking part may give some people access to KarXT, but direct benefit is not guaranteed.

SchizophreniaOtherFrom 5 Years to 17 Years
Countries
Canada, France, Germany, Hungary, Japan, Poland, Romania, Spain, United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
RecruitingNCT06036316

Study of Language Disorders and Interactions Between Mnesic Capabilities and Semantic Competencies in Patients With Psychosis

This study is looking at care and outcomes for people with Psychosis, Schizophrenia, At-risk Mental State, or Language Disorders. Some participants may receive healthy controls instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 16 Years to 55 Years
Countries
France
Sponsor
Centre Psychothérapique de Nancy
Condition
Schizophrenia
RecruitingNCT06361407

Sensory and Cognitive Predictions, and Their Disruptions in Schizophrenia

This study is looking at care and outcomes for people with Schizophrenia or Sensory Processing Disorder. Taking part may give some people access to a digital support tool, but direct benefit is not guaranteed.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
France
Sponsor
Centre Psychothérapique de Nancy
Condition
Schizophrenia
RecruitingNCT06585787

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

This study is looking at how safe and effective KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD is for people with Alzheimer Disease. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Argentina, Belgium, Brazil, Bulgaria, China, Croatia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Poland, Portugal, United States, Romania, Serbia, Slovakia, South Korea, Spain, Turkey, Ukraine
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
RecruitingNCT04370730

Dimensional and Developmental Profiles of Psychosis in Children and Adolescents

This observational study is following people with Schizophrenia or psychosis to understand outcomes over time. Participants mainly provide questionnaire, assessment, or follow-up information rather than receiving a new study treatment.

SchizophreniaOtherFrom 7 Years to 20 Years
Countries
France
Sponsor
Assistance Publique - Hôpitaux de Paris
Condition
Schizophrenia
RecruitingNCT07343193

Deprescribing Antipsychotics: a Multiple Case Study

This observational study is following people with psychosis to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.

SchizophreniaOtherOver 18 Years
Countries
France
Sponsor
University Hospital, Strasbourg, France
Condition
Schizophrenia
RecruitingNCT07003529

Role of Inferior Colliculi in Auditory Hallucinations

This study is looking at care and outcomes for people with Schizophrenia or Hallucinations, Auditory. Some participants may receive Control Group (SCZ+/AH-) instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
France
Sponsor
Centre Hospitalier Universitaire de Nīmes
Condition
Schizophrenia
RecruitingNCT06634641

Clozapine-related Immunodeficiency in Parkinsons Disease

This study is looking at whether blood test can help people with psychosis. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOtherOver 18 Years
Countries
France
Sponsor
Centre Hospitalier Universitaire, Amiens
Condition
Schizophrenia
RecruitingNCT03649581

Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders

This study is looking at compare two subforms of psychotic disorders that have been clinically distinguished in the 1970s for people with Schizophrenia. Taking part may give some people access to compare the two groups of schizophrenic patients, but direct benefit is not guaranteed.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
France
Sponsor
University Hospital, Strasbourg, France
Condition
Schizophrenia
RecruitingNCT05550155

Efficacy of Maintenance Repetitive Transcranial Magnetic Stimulation (rTMS) in Auditory Verbal Hallucinations

This study is looking at whether Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment can help people with Schizophrenia or Psychosis. Participants take part in Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment and complete follow-up assessments.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
France
Sponsor
University Hospital, Caen
Condition
Schizophrenia
RecruitingNCT05980949

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

This study is looking at care and outcomes for people with Psychosis Associated With Alzheimer's Disease. Taking part may give some people access to KarXT, but direct benefit is not guaranteed.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Peru, Poland, Portugal, United States, Romania, Serbia, Slovakia, South Korea, Spain, Turkey, Ukraine, United Kingdom
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
RecruitingNCT07029581

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

This study is looking at care and outcomes for people with Lewy Body Dementia Psychosis. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 55 Years to 84 Years
Countries
Bulgaria, Czech Republic, France, Italy, Serbia, United States
Sponsor
ACADIA Pharmaceuticals Inc.
Condition
Schizophrenia
RecruitingNCT05511363

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

This study is looking at care and outcomes for people with Psychosis Associated With Alzheimer's Disease. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Bulgaria, Croatia, Czech Republic, France, Germany, Italy, Serbia, Slovakia, Spain, United Kingdom, United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
RecruitingNCT06159673

ACP-204 in Adults With Alzheimer's Disease Psychosis

This observational study is following people with Alzheimer's Disease Psychosis to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.

SchizophreniaOtherFrom 55 Years to 95 Years
Countries
Brazil, Bulgaria, Chile, Czech Republic, France, Italy, Mexico, Serbia, South Korea, Spain, Taiwan, United States
Sponsor
ACADIA Pharmaceuticals Inc.
Condition
Schizophrenia
RecruitingNCT05865652

Evaluation of Membrane Phospholipid and Energy Metabolism in Subjects at High Risk of Psychotic Transition

This observational study is following people with With Ultra High Risk of Psychotic Transition to understand outcomes over time. Participants mainly provide questionnaire, assessment, or follow-up information rather than receiving a new study treatment.

SchizophreniaOtherFrom 15 Years to 25 Years
Countries
France
Sponsor
Centre Hospitalier Henri Laborit
Condition
Schizophrenia